Dr Reddy's Laboratories Ltd
(BSP:R1DY34)
R$
12.1
(0%)
Market Cap: 60.48 Bil
Enterprise Value: 60.14 Bil
PE Ratio: 29.54
PB Ratio: 2.55
GF Score: 92/100 Dr.Reddy's Laboratories Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2021 / 04:00PM GMT
Release Date Price:
R$12.84
Neha Manpuria
JPMorgan Chase & Co, Research Division - Analyst
Hello, and welcome to the JPMorgan Healthcare Conference. I am Neha Manpuria, the India Health Care Analyst at JPMorgan. It's my pleasure to introduce Mr. Erez Israeli, the CEO of Dr. Reddy's. We will be having a fireside chat in this session and try to address questions on growth strategies of Reddy's. Thank you so much for joining us for this session, sir. It is a pleasure to host you. If you don't mind me directly moving into Q&A, I can start.
Questions & Answers
Erez Israeli;s Laboratories Limited;CEO;Member of the Management Council
Dr. Reddy
'-&
Sure. Thank you for having me.
Neha Manpuria
JPMorgan Chase & Co, Research Division - Analyst
So the first question that I have is Dr. Reddy's today probably has a very well-balanced business with a growing emerging market presence, improving position in India post the Wockhardt acquisition and a strong U.S. pipeline. From here on,
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot